The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

Basit Öğe Kaydı
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridDiker, Omer/0000-0001-7162-4812
dc.authoridAkin Telli, Tugba/0000-0001-6535-6030
dc.authoridDoğan, İzzet/0000-0003-1018-1119
dc.authorscopusid57204535545
dc.authorscopusid35184520500
dc.authorscopusid26868252200
dc.authorscopusid57369205200
dc.authorscopusid23059468500
dc.authorscopusid57194440555
dc.authorscopusid56024489100
dc.authorwosidAy, Murat/GSI-4353-2022
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidAkin Telli, Tugba/GSE-4006-2022
dc.authorwosidDiker, Omer/GWZ-4666-2022
dc.authorwosidDoğan, İzzet/AAB-6635-2020
dc.contributor.authorÖzdemir, Özlem
dc.contributor.authorZengel, Baha
dc.contributor.authorYıldız, Yaşar
dc.contributor.authorUluç, Başak Oyan
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorOzden, Ercan
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorAvcı, Okan
dc.date.accessioned2023-04-20T08:01:15Z
dc.date.available2023-04-20T08:01:15Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIn our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
dc.identifier.doi10.1097/CAD.0000000000001310
dc.identifier.endpage670
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue7en_US
dc.identifier.pmid35703239
dc.identifier.scopus2-s2.0-85134433317
dc.identifier.scopusqualityQ3
dc.identifier.startpage663
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000001310
dc.identifier.urihttps://hdl.handle.net/20.500.11776/10831
dc.identifier.volume33
dc.identifier.wosWOS:000824584100007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAvcı, Okan
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofAnti-Cancer Drugs
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreast Cancer
dc.subjectNeoadjuvant Chemotherapy
dc.subjectPathological Response
dc.subjectPertuzumab
dc.subjectCarcinoma In-Situ
dc.subjectPathological Complete Response
dc.subjectOpen-Label
dc.subjectChemotherapy
dc.subjectTherapy
dc.subjectTrial
dc.subjectHer2
dc.subjectMulticenter
dc.subjectComponent
dc.subjectNeosphere
dc.titleThe effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu